Alpha-synuclein and the prion hypothesis in Parkinson's disease

被引:26
|
作者
Melki, R. [1 ]
机构
[1] CNRS, Lab Neurodegenerat Dis, CEA, Inst Francois Jacob,MIRCen, 18 Route Panorama, F-92265 Fontenay Aux Roses, France
基金
欧盟地平线“2020”;
关键词
Alpha-synuclein; Parkinson's disease; Multiple system atrophy; Dementia with Lewy bodies; prion-like propagation; PACKING DEFECTS; OLFACTORY-BULB; CELL-DEATH; MEMBRANE; FIBRILS; PATHOLOGY; MUTATION; TRANSMISSION; NEURONS; BRAIN;
D O I
10.1016/j.neurol.2018.08.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Protein intracellular inclusions within the central nervous system are hallmarks of several progressive neurodegenerative disorders in man. The protein constituents of those deposits and the affected regions within the brain differ from one neurodegenerative disorder to another. Until recently, the vicious circle consisting of spread, seeded assembly and accumulation over time within the central nervous system of misfolded proteins aggregates was thought to be restricted to the prion protein PrP. Recent reports suggest that other protein aggregates spread and amplify within the central nervous system leading to distinct diseases. How alpha-synuclein protein assemblies traffic between cells, amplify by recruiting endogenous monomeric alpha-synuclein and cause distinct synucleinopathies is unclear. I review here the experimental evidence supporting the propagation of alpha-synuclein mega-dalton assemblies in a manner similar to prion protein aggregates. I also describe how alpha-synuclein aggregates. I also explain why the aggregation of alpha-synuclein may lead to distinct synucleinopathies. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:644 / 652
页数:9
相关论文
共 50 条
  • [21] Autoantibodies to alpha-synuclein in inherited Parkinson's disease
    Papachroni, Katerina K.
    Ninkina, Natalia
    Papapanagiotou, Angeliki
    Hadjigeorgiou, Georgios M.
    Xiromerisiou, Georgia
    Papadimitriou, Alexandros
    Kalofoutis, Anastasios
    Buchman, Vladimir L.
    JOURNAL OF NEUROCHEMISTRY, 2007, 101 (03) : 749 - 756
  • [22] A Characterization of Misfolded Alpha-Synuclein in Parkinson's Disease
    Shannon, Daniel
    Bugada, John-Paul
    Collins, Ethan
    Fischer, Ellie
    Hellard, Delaney
    Hoffman, Trevor
    Kellogg, Nick
    Peters, Kyle
    Poetker, Garret
    Young, Logan
    Diao, JiaJie
    FASEB JOURNAL, 2020, 34
  • [23] Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
    Dolgacheva L.P.
    Fedotova E.I.
    Abramov A.Y.
    Berezhnov A.V.
    Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology, 2018, 12 (1) : 10 - 19
  • [24] Alpha-synuclein and presynaptic functionImplications for Parkinson’s disease
    Simon Lykkebo
    Poul Henning Jensen
    NeuroMolecular Medicine, 2002, 2 : 115 - 129
  • [25] Role of alpha-synuclein and tau in Parkinson's disease
    Trojanowski, JQ
    MOVEMENT DISORDERS, 2004, 19 : S2 - S2
  • [26] Targeting Alpha-Synuclein for the Treatment of Parkinson's Disease
    Rohn, Troy T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (02) : 174 - 179
  • [27] The central role of alpha-synuclein in Parkinson's disease
    Halliday, G.
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 54 - 54
  • [28] Alpha-synuclein and the Parkinson's disease drug pipeline
    Espay, Alberto J.
    McFarthing, Kevin
    PARKINSONISM & RELATED DISORDERS, 2023, 111
  • [29] Colonic Expression of Alpha-Synuclein in Parkinson's Disease
    Hefti, Marco
    Goldsmith, Jeffrey
    Pfannl, Rolf
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2015, 74 (06): : 597 - 597
  • [30] Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease
    Ma, Ling-Yan
    Liu, Gen-Liang
    Wang, Dong-Xu
    Zhang, Mei-Mei
    Kou, Wen-Yi
    Feng, Tao
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (02): : 812 - 823